Corrigendum to: Untangling Breast Cancer: Trailing Towards Nanoformulations-based Drug Development.
Authors
Affiliations (10)
Affiliations (10)
- Department of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani, Haryana, 127021, India.
- Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India.
- Shrinathji Institute of Pharmacy, Shrinathji Society for Higher Education, Upali Oden, Nathdwara, Rajasmand, Rajasthan, India.
- Department of Pharmacy, G.D. Goenka University, Sohna Road, Gurugram, 122103, India.
- School of Pharmaceutical Sciences, CT University, Ludhiana, 142024, Punjab, India.
- Bhabha Pharmacy Research Institute, Bhabha University Bhopal, 462026, Madhya Pradesh, India.
- PRISAL Foundation, Pharmaceutical Royal International Society, New Delhi, India.
- Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, India.
- Pharmacy Academy, IFTM University, Lodhipur Rajput, Moradabad, U.P., 244102, India.
- Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Abstract
Following publication of the article entitled "Untangling Breast Cancer: Trailing Towards Nanoformulations-based Drug Development" [1], certain phrases and expressions were identified that were unclear or inconsistent with established scientific terminology. To ensure accuracy and clarity of the published record, these expressions have been corrected using appropriate terminology that more accurately conveys the intended scientific meaning. These corrections are limited to the wording and terminology of the affected passages and do not alter the data, results, scientific interpretations, or conclusions of the article. The specific corrections are provided below: Section: 1.2.1.3. Metastatic BC, Paragraph: 1 Original text: Patients identified with metastatic illness (or de novo metastatic BC) at the outset of treatment may progress metastases months or years later. Unluckily, approximately 30% of females diagnosed with early-stage BC will go on to develop metastatic illness [22]. Corrected text: Patients identified with metastatic cancer (or de novo metastatic BC) at the outset of treatment may progress metastases months or years later. Unluckily, approximately 30% of females diagnosed with early-stage BC will go on to develop metastatic cancer [22]. Section: 3.3. Micelles: A Miracle Ball in BC Therapy, Paragraph: 1 Original text: These are solitary layer amphiphilic self-assembly networks, made by recapping entities of surfactant atoms [50]. Corrected text: These are single-layer amphiphilic self-assembly networks, made by recapping entities of surfactant atoms [50]. Section: 6. ROLE OF ARTIFICIAL INTELLIGENCE, Paragraph: 5 Original text: Du et al., (2022) create an artificial intelligence application that uses ultrasound (US) images to diagnose breast illness. To classify breast suspicious lesions as benign, malignant, or normal, a deep learning algorithm called Efficient-Det was created [119]. Breast cancer diagnosis utilizing breast ultrasound pictures was proposed by Qi et al., deep neural networks [120] were used in this manner. Corrected text: Du et al., (2022) create an artificial intelligence application that uses ultrasound (US) images to diagnose breast cancer. To classify breast suspicious lesions as benign, malignant, or normal, a deep learning algorithm called Efficient-Det was created [119]. Qi et al developed deep neural frameworks that can automatically diagnose breast cancer with help of ultrasonic images of breast [120] . The original article has been updated accordingly. This Corrigendum is published to ensure transparency and accuracy of the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/133241 The authors regret these errors and apologise for any inconvenience they may have caused.